Litcius/Paper detail

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

Antoinette R. Tan, Seock‐Ah Im, André Mattar, Rámón Colomer, Daniil Stroyakovskii, Zbigniew Nowecki, Michelino De Laurentiis, Jean‐Yves Pierga, Kyung Hae Jung, Christian Schem, Alexandra Hogea, Tanja Badovinac Črnjević, Sarah Heeson, Mahesh Shivhare, Whitney P. Kirschbrown, Eleonora Restuccia, Christian Jackisch

2020The Lancet Oncology166 citationsDOI

Topics & Concepts

PertuzumabTrastuzumabMedicineBreast cancerLoading doseInternal medicineRegimenOncologyMetastatic breast cancerClinical endpointCancerClinical trialHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesPeptidase Inhibition and Analysis
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study | Litcius